

Indian Hospital Industry

Industry to continue to witness robust performance in FY2026 and FY2027; outlook revised to Positive

July 2025



Highlights





The business outlook for the Indian hospital industry has been revised to Positive from Stable, reflecting expectations of continued robust operating metrics supported by strong structural tailwinds.

Despite sizeable greenfield and brownfield expansions planned across metros, tier-II and tier-III cities, the credit profile of ICRA's sample set companies is anticipated to remain healthy given the strong accrual expectations.







• ICRA's sample set¹ of hospital companies is expected to witness robust revenue growth of 16-18% in FY2026, supported by continued healthy occupancy and healthy average revenue per occupied bed (ARPOB). Further, continued benefits from cost optimisation measures will support healthy operating profit margin (OPM) of 22-24% in FY2026 in line with OPM of 23.6% in FY2025.



Aggregate occupancy for ICRA's sample set of companies is estimated to remain healthy at 62-64% in FY2026, in line with 63.5% in FY2025, supported by continued buoyant demand for healthcare services.



■ The ARPOB growth for ICRA's sample set is projected to range between 6-8% in FY2026, post a robust 11% and 7% increase in ARPOB in FY2024 and FY2025, respectively, given the large base in addition to expansion in tier-II and tier-III cities wherein ARPOB is lower than that in metros.



■ Several companies in the sample set have announced sizeable acquisition, expansion and upgradation/ refurbishment plans over the next four to five years. They are expected to add over 9,900 beds and 4,500 beds in FY2026 and FY2027, respectively, at a cumulative investments of Rs. 30,000-32,000 crore.



■ Despite the sizeable ongoing capex, the total debt/OPBDITA for ICRA's sample set companies is likely to rise but remain healthy at 2.4-2.6x as on March 31, 2026, and the return on capital employed (RoCE) will remain at 14-16% in FY2026, despite sizeable ongoing capex.

¹ICRA's sample set includes the hospital business of eleven listed and two unlisted companies, Apollo Hospitals Enterprise Limited, Aster DM Healthcare Limited, Fortis Healthcare Limited, Global Health Limited, Healthcare Global Enterprises Limited, Jupiter Life Line Hospitals, Krishna Institute of Medical Sciences Limited, Manipal Health Enterprises Pvt Limited, Max Healthcare Institute Limited, Narayana Hrudayalaya Limited, Quality Care India Limited, Rainbow Children's Medicare Limited and Shalby Limited.

Agenda













Name	Designation	Email	Contact Number
Jitin Makkar	Senior Vice-President and Group Head	jitinm@icraindia.com	0124 – 4545 300
Kinjal Shah	Senior Vice-President and Co-Group Head	kinjal.shah@icraindia.com	022 – 6114 3442
Mythri Macherla	Vice President and Sector Head	mythri.macherla@icraindia.com	022 – 6114 3435
Aman Mundhada	Analyst	aman.mundhdada@icraindia.com	022 – 6114 3471

















ICRA Business Development/Media Contact Details

Name	Designation	Email	Contact Number
L Shivakumar	Chief Business Officer	shivakumar@icraindia.com	022-61693304
Neha Agarwal	Head – Research Sales	neha.agarwal@icraindia.com	022-61693338
Rohit Gupta	Head Business Development – Infrastructure Sector	rohitg@icraindia.com	0124-4545340
Vivek Bhalla	Head Business Development – Financial Sector	vivek.bhalla@icraindia.com	022-61693372
Vinita Baid	Head Business Development – East	vinita.baid@icraindia.com	033-65216801
Shivam Bhatia	Head Business Development – Corporate Sector – North & South	shivam.bhatia@icraindia.com	0124-4545803
Sanket Kulkarni	Head Business Development – Corporate Sector – West	sanket.kulkarni@icraindia.com	022-6169 3365
Naznin Prodhani	Head - Group Corporate Communications & Media Relations	communications@icraindia.com	0124-4545860



















© Copyright, 2025 ICRA Limited. All Rights Reserved.

All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable. Although reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies, while publishing or otherwise disseminating other reports may have presented data, analyses and/or opinions that may be inconsistent with the data, analyses and/or opinions in this publication. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.



Thank You!

